Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Centessa Pharmaceuticals PLC (NASDAQ:CNTA) Chief Business Officer Gregory M. Weinhoff sold 10,000 ordinary shares of the company on June 25, 2025, for a total of $138,642. The shares were sold at prices ranging from $13.60 to $14.06. On the same day, Weinhoff also exercised options to acquire 10,000 ordinary shares at a price of $3.85, for a total value of $38,500. The transaction comes as the $1.9 billion market cap company has seen its stock surge over 51% in the past year, according to InvestingPro data. The company maintains a strong balance sheet with more cash than debt.
Following these transactions, Weinhoff directly owns 122,279 ordinary shares of Centessa Pharmaceuticals.
The sale was executed under a Rule 10b5-1 trading plan adopted by Weinhoff on May 22, 2024.
In other recent news, Centessa Pharmaceuticals has appointed Raphael Deferiere as its new Chief Accounting Officer, effective May 27, 2025. Deferiere, who has an extensive background with Ernst & Young, will also serve as the principal accounting officer of the company. Piper Sandler has maintained its Overweight rating on Centessa Pharmaceuticals, setting a price target of $38.00, based on the potential of the company’s orexin 2 receptor (OX2R) agonist treatments for sleep disorders like narcolepsy and idiopathic hypersomnia. This endorsement follows discussions with a sleep medicine specialist and anticipates key data from the Phase 2 CRYSTAL-1 study later this year. Additionally, BMO Capital Markets reiterated its Outperform rating with a $35.00 price target, expressing confidence in the ORX750 drug candidate for narcolepsy and idiopathic hypersomnia. The firm estimates an 80% probability of success for the Phase II trials, highlighting the drug’s potential to improve wakefulness without visual side effects. Centessa’s pipeline, including other orexin agonist programs, is noted for its potential to expand the company’s market reach. Investors are closely watching for upcoming clinical data that could influence Centessa’s position in the sleep disorder treatment market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.